235 related articles for article (PubMed ID: 15171958)
1. Platelet glycoprotein IIb/IIIa inhibitors.
Rosove MH
Best Pract Res Clin Haematol; 2004 Mar; 17(1):65-76. PubMed ID: 15171958
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
5. Anti-GPIIb/IIIa drugs: current strategies and future directions.
Coller BS
Thromb Haemost; 2001 Jul; 86(1):427-43. PubMed ID: 11487034
[TBL] [Abstract][Full Text] [Related]
6. Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery.
Cheng DK; Jackevicius CA; Seidelin P; Feindel C; Rouleau JL
Can J Cardiol; 2004 Feb; 20(2):223-8. PubMed ID: 15010747
[TBL] [Abstract][Full Text] [Related]
7. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
[TBL] [Abstract][Full Text] [Related]
8. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
9. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
[TBL] [Abstract][Full Text] [Related]
10. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
11. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
Witkowski A; Maciejewski P; Wasek W; Malek LA; Niewada M; Kaminski B; Drzewiecki J; Kosmider M; Kubica J; Ruzyllo W; Peruga JZ; Dudek D; Opolski G; Dobrzycki S; Gil RJ;
Eur Heart J; 2009 Jul; 30(14):1736-43. PubMed ID: 19376786
[TBL] [Abstract][Full Text] [Related]
12. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes.
Lepor NE
Rev Cardiovasc Med; 2002; 3 Suppl 1():S3-S12. PubMed ID: 12439431
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
[TBL] [Abstract][Full Text] [Related]
14. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
Harrington RA
Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
[TBL] [Abstract][Full Text] [Related]
15. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Juran NB
Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
[TBL] [Abstract][Full Text] [Related]
16. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
[TBL] [Abstract][Full Text] [Related]
17. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
18. Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.
Tcheng JE
J Interv Cardiol; 2006 Oct; 19(5):456-63. PubMed ID: 17020571
[TBL] [Abstract][Full Text] [Related]
19. Current strategies with high-dose tirofiban.
Mukherjee D; Roffi M
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156
[TBL] [Abstract][Full Text] [Related]
20. Eptifibatide and tirofiban: new preparations. Limited benefit.
Prescrire Int; 2000 Oct; 9(49):135-8. PubMed ID: 11603412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
